Anthropic reported on October 27, 2026 that Claude has spent several months inside real drug programs, with six partner organizations and one program of its own. The partners are BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group. Anthropic’s framing is that there is no single breakthrough to chase: “There is no single problem to solve; the bottlenecks are distributed all throughout the drug development process.”
That is why the results span very different jobs, from designing antibodies to checking manufacturing paperwork. This page is read from Anthropic’s post and its technical report on the muscular dystrophy program.
Anthropic published early results on October 27, 2026 from research partnerships with six drug developers, including Bristol Myers Squibb, Generate Biomedicines and Enveda.
Divergence Labs used Claude to generate roughly 35,000 antibody designs in about a month; three of the 20 that dislodged IgE did so more than the standard medication.
At Enveda, Claude caught all 11 issues human reviewers found in 1,061 pages of manufacturing records, flagged seven more, and cut review time by 89%.
Anthropic acquired Mithril Medicine, a one-person muscular dystrophy company, and says a drug could start human trials as soon as late 2028.
Almost all of it is preclinical: the drugs are not yet being tested in people, and the technical reports are not peer reviewed.
§ 01What Claude did at each partner
| Partner | Stage of the work | What Anthropic reports |
|---|---|---|
| Generate Biomedicines | Engineering a CAR T-cell therapy for solid tumors | Six scientists used Claude Code; one design about 70% shorter let immune cells make roughly 10 times as many receptors |
| Divergence Labs | Finding first candidates for a food-allergy drug | About 35,000 antibody designs in about a month; 3 bound IgE and 20 dislodged it, 3 more than the standard medication (preprint) |
| BigHat Biosciences | Improving two antibody fragments | About 1,010 variants made and tested in about 10 weeks; best versions bound more than 10x more tightly |
| Enveda | Manufacturing records and regulatory filings | Review time down 89%; one regulatory draft took four hours instead of about three months |
| The Column Group | Starting a company run on Claude | New company Pleiades; its first Claude skill evaluated on 45 target-disease pairs |
| Bristol Myers Squibb | Clinical trial planning | Claude assesses early-stage trial plans and estimates their chance of success; work expands in 2027 |
The BigHat case adds a detail worth noticing. Partway through, the team suspected the standard heat-stability and clumping metrics were misleading; Claude and an Anthropic researcher reanalyzed the raw data and proposed different metrics, and BigHat’s scientists ran the revised protocol. One lead stayed in solution at a temperature 18°C higher, and the other clumped more than 100x more slowly.
§ 02The paperwork result
Enveda’s chemists spent up to 75% of their time on documentation. Enveda connected its manufacturing documents to Claude and had it flag possible issues, then compared the result with human review.
| Finding | Count |
|---|---|
| Issues human reviewers found | 11 |
| Of those, caught by Claude | 11 |
| Extra issues Claude flagged that humans missed | 7 |
Review time fell from over 25 hours to less than three. On a second regulatory document Claude drafted, Enveda’s standard human review found one minor error. For Bristol Myers Squibb, the quote Anthropic published is about speed rather than science: “From a single prompt, Claude generated a robust initial analysis that helped inform our assessment of different development options, which would otherwise take days to complete.”
§ 03Anthropic’s own drug program
Anthropic acquired Mithril Medicine, a one-person company working on two rare forms of muscular dystrophy. Its founder, Cody Tranbarger, used Claude to organize contracts, logistics and experiments with 11 external labs, and took a possible treatment from idea to promising results in mice in less than 18 months. He continues the work at Anthropic.
The technical report, dated October 26, 2026 and marked not peer reviewed, covers LAMA2-related congenital muscular dystrophy, a childhood disease with no disease-modifying treatment. The approach is an antibody that bridges a related protein the muscle still makes to the muscle cell membrane. In a pilot study, mice treated with the tetravalent version developed about twice the peak force and grip strength of untreated mice. Anthropic says a drug could be ready for human trials as soon as late 2028.
§ 04What it means
The pattern across these cases is that Claude did most for teams when it was connected to their real systems: BigHat’s lab data, Enveda’s document store, Mithril’s lab contracts. The gains came less from one clever molecule and more from compressing the slow, distributed work around it. Anthropic is also widening access through Claude Science, credits for life scientists and a Life Sciences Verification Program for trusted organizations.
The honest limit is stated in the post itself: the research is “mostly preclinical”, meaning the drugs are not yet being tested in humans. None of these results is a medicine yet, and the reports have not been through peer review.
§ 05What to watch
- Whether Divergence Labs builds a drug combining its two antibody arms, its stated next step.
- Peer review or independent replication of any of the technical reports.
- Bristol Myers Squibb’s expanded 2027 work on clinical trial planning.
- Mithril’s program reaching the clinic, which Anthropic puts as soon as late 2028.
Q1Who are Anthropic's drug-development partners?
BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group, which is setting up a new company called Pleiades to run on Claude.
Q2What did Claude do at Enveda?
It reviewed 1,061 pages of manufacturing documents, catching all 11 issues human reviewers had found plus seven they missed, and drafted a regulatory document in four hours that took about three months by hand.
Q3What is Mithril Medicine?
A one-person company Anthropic acquired. Its founder used Claude to coordinate 11 external labs and took a muscular dystrophy treatment from idea to promising mouse results in less than 18 months.
Q4Can other researchers use this?
Anthropic points to Claude Science, its workbench for researchers, credits for life scientists, a Life Sciences Verification Program with more permissive safeguards for trusted groups, and an open call for guest investigators.
Q5How reliable are the results?
They are early. Most work is preclinical, the partner and Anthropic technical reports are not peer reviewed, and the mouse study is described as a pilot.